Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
J Med Chem. 2013 Aug 22;56(16):6495-511. doi: 10.1021/jm400807n. Epub 2013 Aug 13.
Tankyrase 1 and 2 have been shown to be redundant, druggable nodes in the Wnt pathway. As such, there has been intense interest in developing agents suitable for modulating the Wnt pathway in vivo by targeting this enzyme pair. By utilizing a combination of structure-based design and LipE-based structure efficiency relationships, the core of XAV939 was optimized into a more stable, more efficient, but less potent dihydropyran motif 7. This core was combined with elements of screening hits 2, 19, and 33 and resulted in highly potent, selective tankyrase inhibitors that are novel three pocket binders. NVP-TNKS656 (43) was identified as an orally active antagonist of Wnt pathway activity in the MMTV-Wnt1 mouse xenograft model. With an enthalpy-driven thermodynamic signature of binding, highly favorable physicochemical properties, and high lipophilic efficiency, NVP-TNKS656 is a novel tankyrase inhibitor that is well suited for further in vivo validation studies.
Tankyrase 1 和 2 已被证明在 Wnt 通路中是冗余的、可成药的节点。因此,人们强烈关注开发合适的药物来通过靶向该酶对在体内调节 Wnt 通路。通过结合基于结构的设计和基于 LipE 的结构效率关系,XAV939 的核心被优化为更稳定、更高效但效力较低的二氢吡喃基 motif 7。该核心与筛选命中化合物 2、19 和 33 的部分元素结合,产生了高度有效、选择性的 tankyrase 抑制剂,是新型三口袋结合物。NVP-TNKS656(43)被鉴定为 MMTV-Wnt1 小鼠异种移植模型中 Wnt 通路活性的口服拮抗剂。具有驱动力为焓的结合热力学特征、非常有利的物理化学性质和高亲脂效率,NVP-TNKS656 是一种新型的 tankyrase 抑制剂,非常适合进一步的体内验证研究。